NASDAQ:TNGX Tango Therapeutics (TNGX) Stock Price, News & Analysis $9.75 -0.10 (-1.02%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.58▼$10.1550-Day Range$6.66▼$10.1552-Week Range$2.88▼$13.03Volume811,585 shsAverage Volume692,087 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$14.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Tango Therapeutics alerts: Email Address Tango Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.13 Rating ScoreUpside/Downside52.4% Upside$14.86 Price TargetShort InterestBearish15.26% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 8 Articles This WeekInsider TradingSelling Shares$12.62 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.35) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.35 out of 5 starsMedical Sector561st out of 936 stocksPharmaceutical Preparations Industry255th out of 436 stocks 4.6 Analyst's Opinion Consensus RatingTango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTango Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tango Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.26% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Tango Therapeutics has recently increased by 1.92%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTango Therapeutics does not currently pay a dividend.Dividend GrowthTango Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TNGX. Previous Next 2.4 News and Social Media Coverage News SentimentTango Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Tango Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for TNGX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tango Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,620,455.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Tango Therapeutics is held by insiders.Percentage Held by Institutions78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tango Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.35) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tango Therapeutics is -8.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tango Therapeutics is -8.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTango Therapeutics has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tango Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Tango Therapeutics Stock (NASDAQ:TNGX)Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.Read More TNGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TNGX Stock News HeadlinesJuly 25 at 6:22 AM | insidertrades.comTango Therapeutics, Inc. (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 262,740 SharesJuly 19, 2024 | insidertrades.comTango Therapeutics, Inc. (NASDAQ:TNGX) Major Shareholder Sells $5,386,174.09 in StockJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 3, 2024 | insidertrades.comTango Therapeutics, Inc. (NASDAQ:TNGX) Insider Mva Investors, Llc Sells 29,000 SharesJuly 3, 2024 | insidertrades.comMva Investors, Llc Sells 110,731 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) StockJuly 22, 2024 | americanbankingnews.comHead-To-Head Survey: Indivior (OTCMKTS:INVVY) and Tango Therapeutics (NASDAQ:TNGX)July 20, 2024 | americanbankingnews.comRock Ventures Iv L.P. Third Sells 550,171 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) StockJuly 19, 2024 | msn.comJefferies Initiates Coverage of Tango Therapeutics (TNGX) with Buy RecommendationJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 17, 2024 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Research Coverage Started at Jefferies Financial GroupJune 5, 2024 | businesswire.comTango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Tango Therapeutics (TNGX)May 23, 2024 | prnewswire.comMedivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programMay 23, 2024 | reuters.comTango Therapeutics to stop development of cancer therapyMay 23, 2024 | businesswire.comTango Therapeutics Announces Discontinuation of TNG348 ProgramMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tango Therapeutics on Promising PRMT5 Inhibitors and Strong FinancialsMay 8, 2024 | investorplace.comTNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | businesswire.comTango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business HighlightsSee More Headlines Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TNGX CUSIPN/A CIK1819133 Webwww.tangotx.com Phone857-320-4900FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$14.86 High Stock Price Target$19.00 Low Stock Price Target$11.00 Potential Upside/Downside+52.4%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,740,000.00 Net Margins-299.88% Pretax Margin-299.41% Return on Equity-44.35% Return on Assets-27.63% Debt Debt-to-Equity RatioN/A Current Ratio8.23 Quick Ratio8.23 Sales & Book Value Annual Sales$36.53 million Price / Sales28.52 Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book3.93Miscellaneous Outstanding Shares106,850,000Free Float100,222,000Market Cap$1.04 billion OptionableOptionable Beta0.83 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Barbara L. Weber M.D. (Age 67)President, CEO & Director Comp: $1.04MDr. Adam S. Crystal M.D. (Age 47)Ph.D., President of Research & Development Comp: $977.22kDr. Alan Ashworth FRS (Age 63)Ph.D., Founder & Member of Scientific Advisory Board Dr. Levi Garraway M.D. (Age 55)Ph.D., Founder Dr. William G. Kaelin Jr. (Age 66)M.D., Founder & Member of Scientific Advisory Board Dr. Timothy K. Lu M.D. (Age 43)Ph.D., Founder Dr. Antoni Ribas M.D. (Age 57)Ph.D., Founder & Member of Scientific Advisory Board Mr. Timothy Redfern (Age 45)Chief Financial Officer Mr. Jannik N. Andersen Ph.D.Chief Scientific OfficerMr. Douglas J. Barry Esq. (Age 54)J.D., Chief Legal Officer, Chief Compliance Officer & Corporate Secretary More ExecutivesKey CompetitorsOusterNYSE:OUSTCompoSecureNASDAQ:CMPOEos Energy EnterprisesNASDAQ:EOSEDocGoNASDAQ:DCGOPorch GroupNASDAQ:PRCHView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 15,373 shares on 7/26/2024Ownership: 0.133%Rock Ventures Iv L.P. ThirdSold 200,000 sharesTotal: $1.96 M ($9.82/share)Rock Ventures Iv L.P. ThirdSold 262,740 sharesTotal: $2.57 M ($9.78/share)Rock Ventures Iv L.P. ThirdSold 550,171 sharesTotal: $5.39 M ($9.79/share)Simplicity Wealth LLCBought 16,080 shares on 7/10/2024Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions TNGX Stock Analysis - Frequently Asked Questions How have TNGX shares performed this year? Tango Therapeutics' stock was trading at $9.90 at the start of the year. Since then, TNGX stock has decreased by 1.5% and is now trading at $9.75. View the best growth stocks for 2024 here. How were Tango Therapeutics' earnings last quarter? Tango Therapeutics, Inc. (NASDAQ:TNGX) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.04. The company had revenue of $6.47 million for the quarter, compared to analyst estimates of $7.13 million. Tango Therapeutics had a negative trailing twelve-month return on equity of 44.35% and a negative net margin of 299.88%. Who are Tango Therapeutics' major shareholders? Tango Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.13%) and Simplicity Wealth LLC (0.04%). Insiders that own company stock include Rock Ventures Iv LP Third, Boxer Capital, Llc, Mva Investors, Llc, Daniella Beckman and Douglas Barry. View institutional ownership trends. How do I buy shares of Tango Therapeutics? Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TNGX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
